Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions

Cancer Science

Volumn 98, Issue 8, 2007, Pages 1139-1146

  Akatsuka, Yoshiki ^a   Morishima, Yasuo ^a   Kuzushima, Kiyotaka ^a   Kodera, Yoshihisa ^b   Takahashi, Toshitada ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTINEOPLASTIC AGENT; DNA VACCINE; HLA A3 ANTIGEN; HLA B7 ANTIGEN; LEUKOCYTE ANTIGEN; LIVER RECEPTOR HOMOLOG 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE FRAGMENT; PROTEIN BCL 2; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DONOR; DRUG TARGETING; GENETIC CODE; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNITY; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; T LYMPHOCYTE;

EPITOPES; GRAFT VS LEUKEMIA EFFECT; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MINOR HISTOCOMPATIBILITY ANTIGENS; MODELS, BIOLOGICAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 34347270987     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00521.x     Document Type: Review

References (66)

1. Goulmy E. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-40.
2. Riddell SR, Berger C, Murata M et al. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17: 153-62.
3. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-5.
4. Burroughs L, Storb R. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: Separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol 2005; 12: 45-54.
5. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.
6. Tykodi SS, Warren EH, Thompson JA et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: Toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799-811.
7. Meunier MC, Delisle JS, Bergeron J et al. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005; 11: 1222-9.
8. Fontaine P, Roy-Proulx G, Knafo L et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001; 7: 789-94.
9. Chen BJ, Cui X, Sempowski GD et al. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 2004; 103: 1534-41.
10. Dickinson AM, Wang XN, Sviland L et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410-14.
11. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-7.
12. Klein CA, Wilke M, Pool J et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med 2002; 196: 359-68.
13. Miyazaki M, Akatsuka Y, Nishida T et al. Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. Clin Immunol 2003; 107: 198-201.
14. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-5.
15. Mutis T, Verdijk R, Schrama E et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-41.
16. Hambach L, Nijmeijer BA, Aghai Z et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 2006; 20: 371-4.
17. de Rijke B, van Horssen-Zoetbrood A, Beekman JM et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115: 3506-16.
18. Brickner AG, Evans AM, Mito JK et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 2006; 107: 3779-86.
19. Kawase T, Akatsuka Y, Torikai H et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 2007 Apr 4; [Epub ahead of print].
20. Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-7.
21. Nishida T, Akatsuka Y, Morishima Y et al. Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. Br J Haematol 2004; 124: 629-35.
22. Spierings E, Brickner AG, Caldwell JA et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 2003; 102: 621-9.
23. Warren EH, Vigneron NJ, Gavin MA et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006; 313: 1444-7.
24. Brickner AG, Warren EH, Caldwell JA et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001; 193: 195-206.
25. Pierce RA, Field ED, Mutis T et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol 2001; 167: 3223-30.
26. den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476-80.
27. Torikai H, Akatsuka Y, Miyazaki M et al. The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303. Br J Haematol 2006; 134: 406-16.
28. Dolstra H, de Rijke B, Fredrix H et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J Immunol 2002; 32: 2748-58.
29. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301-8.
30. Akatsuka Y, Nishida T, Kondo E et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med 2003; 197: 1489-500.
31. Slager EH, Honders MW, van der Meijden ED et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006; 107: 4954-60.
32. Mommaas B, Kamp J, Drijfhout JW et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 2002; 169: 3131-6.
33. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197: 1279-89.
34. Maruya E, Saji H, Seki S et al. Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants. Blood 1998; 92: 2169-76.
35. Yazaki M, Takahashi T, Andho M et al. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Bone Marrow Transplant 1999; 24: 129-37.
36. Torikai H, Akatsuka Y, Miyauchi H et al. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. Bone Marrow Transplant (in press).
37. Itoh Y, Mizuki N, Shimada T et al. High-throughput DNA typing of HLA-A-B-C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005; 57: 717-29.
38. Akatsuka Y, Kondo E, Taji H et al. Targeted cloning of cytotoxic T cells specific for minor histocompatibility antigens restricted by HLA class I molecules of interest. Transplantation 2002; 74: 1773-80.
39. Akatsuka Y, Goldberg TA, Kondo E et al. Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 2002; 59: 502-11.
40. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18: 798-808.
41. Gubarev MI, Jenkin JC, Leppert MF et al. Localization to chromosome 22 of a gene encoding a human minor histocompatibility antigen. J Immunol 1996; 157: 5448-54.
42. Wang CY, Guttridge DC, Mayo MW et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-9.
43. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA et al. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: Relevance for allogeneic immunotherapy of leukemia. Blood 2005; 106: 3955-7.
44. Akatsuka Y, Torikai H, Inamoto Y et al. Bone marrow may be a reservoir of long-lived memory T cells specific for minor histocompatibility antigen. Br J Haematol 2006; 135: 413-14.
45. van Bergen C, Kester M, Jedema I et al. Multiple myeloma reactive T cells recognize an activation induced minor histocompatibility antigen encoded by the ATP dependent interferon responsive (ADIR) gene. Blood 2007; 109: 4089-96.
46. The International HapMap Project. Nature 2003; 426: 789-96.
47. Ito M, Hiramatsu H, Kobayashi K et al. NOD/SCID/gamma (c) (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-82.
48. Bonnet D, Warren EH, Greenberg PD et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 8639-44.
49. Kircher B, Wolf M, Stevanovic S et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. J Immunother 2004; 27: 156-60.
50. Warren EH, Kelley DM, Brown ML et al. Adoptive GVL therapy targeting minor histocompatibility antigens for the treatment of posttransplant leukemia relapse -update of the FHCRC experience. Blood 2002; 100: 633a.
51. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
52. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
53. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006; 12: 2342S-5S.
54. Rice J, Dunn S, Piper K et al. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. Cancer Res 2006; 66: 5436-42.
55. Spierings E, Goulmy E. Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest 2005; 115: 3397-400.
56. Verdijk RM, Kloosterman A, Pool J et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: Implications for stem cell transplantation and immunotherapy. Blood 2004; 103: 1961-4.
57. Spierings E, Drabbels J, Hendriks M et al. A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS ONE 2006; 1: E42.
58. Wang W, Meadows LR, den Haan JM et al. Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588-90.
59. Pierce RA, Field ED, den Haan JM et al. Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 1999; 163: 6360-4.
60. Warren EH, Gavin MA, Simpson E et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000; 164: 2807-14.
61. Vogt MH, Goulmy E, Kloosterboer FM et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: Characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000; 96: 3126-32.
62. Vogt MH, van den Muijsenberg JW, Goulmy E et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-32.
63. Zorn E, Miklos DB, Floyd BH et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004; 199: 1133-42.
64. Spierings E, Vermeulen CJ, Vogt MH et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet 2003; 362: 610-15.
65. Ivanov R, Aarts T, Hol S et al. Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response. Clin Cancer Res 2005; 11: 1694-703.
66. Torikai H, Akatsuka Y, Miyazaki M et al. A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J Immunol 2004; 173: 7046-54.